{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T01:36:20Z","timestamp":1772933780106,"version":"3.50.1"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,8,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma or another related plasma cell disorder (PCD) at a rate of approximately 1% per year. Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients were eligible for this retrospective analysis if they were seen at the Mayo Clinic between 1984 and 1997, were diagnosed with MGUS, and had an analysis of the peripheral blood for circulating PCs by the slide-based immunofluorescence method. Patients were observed for progression to another PCD. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Three hundred twenty-five patients were eligible and 63 (19%) had circulating PCs. Patients with circulating PCs were twice as likely (hazard ratio, 2.1) to experience progression to another PCD (most commonly myeloma), compared with those without circulating PCs (95% CI, 1.1 to 4.3; P = .03). In patients with circulating PCs, the median progression-free survival was 138 months compared with a median not yet reached for those without circulating PCs (P = .028). The median overall survival also was shorter for those with circulating PCs. Other factors with prognostic value were high levels of M protein and non\u2013immunoglobulin G heavy-chain type. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The presence of circulating PCs, especially when combined with other known prognostic factors such as M protein concentration and immunoglobulin isotype, identify a group of individuals with MGUS at higher risk of progression to overt multiple myeloma. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.03.159","type":"journal-article","created":{"date-parts":[[2005,8,18]],"date-time":"2005-08-18T22:18:02Z","timestamp":1124403482000},"page":"5668-5674","source":"Crossref","is-referenced-by-count":107,"title":["Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance"],"prefix":"10.1200","volume":"23","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V40.5.719.719"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.35.1.63"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Axelsson U: A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand 219:519,1986-522,","DOI":"10.1111\/j.0954-6820.1986.tb03349.x"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.859"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70120-9"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200001)63:1<1::AID-AJH1>3.0.CO;2-M"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1625"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19960615)26:2<113::AID-CYTO3>3.0.CO;2-H"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.6.1041"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04908.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.5.1780.1780"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1698"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930701)72:1<108::AID-CNCR2820720121>3.0.CO;2-T"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Boccadoro M, Omede P, Massaia M, et al: Human myeloma: Several subsets of circulating lymphocytes express plasma cell-associated antigens. Eur J Haematol 40:299,1988-304,","DOI":"10.1111\/j.1600-0609.1988.tb00181.x"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.7.1375.1375"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V55.4.590.590"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Witzig TE, Kyle RA, Greipp PR: Circulating peripheral blood plasma cells in multiple myeloma. Curr Top Microbiol Immunol 182:195,1992-199,","DOI":"10.1007\/978-3-642-77633-5_23"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08378.x"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.1.289.289"},{"key":"R25","unstructured":"Cassel A, Leibovitz N, Hornstein L, et al: Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients. Exp Hematol 18:1171,1990-1173,"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07646.x"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Osterborg A, Nilsson B, Bjorkholm M, et al: Blood clonal B cell excess at diagnosis in multiple myeloma: Relation to prognosis. Eur J Haematol 38:173,1987-178,","DOI":"10.1111\/j.1600-0609.1987.tb01158.x"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.294826.x"},{"key":"R29","unstructured":"Gregersen H, Mellemkjaer L, Ibsen JS, et al: The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 86:1172,2001-1179,"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.11.1921"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.03.159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:12:00Z","timestamp":1653513120000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.03.159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,20]]},"references-count":29,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2005,8,20]]}},"alternative-id":["10.1200\/JCO.2005.03.159"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.03.159","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,20]]}}}